(+34) 93 414 55 66
Contact
Espacio socios y amigos
Starting this January, the Josep Carreras Leukaemia Research Institute (IJC) will have a new high-profile research team focused on flow cytometry, which will add important experience and great recognition in the field, brought by biologist Dr. Jordi Petriz.
Dr.Petriz, who has been an expert in this discipline for more than two decades, has a broad international career, although his decision and commitment to continue developing his investigations in his home country are worth mentioning, for he has become one of the main representatives of flow cytometry in Spain.
This Catalan researcher who has developed his career as a researcher in the Vall d’Hebron Hospital Research Institute (VHIR) over the last few years, is internationally renown for his contribution to the field of study of stem cells, both for developing techniques to isolate and cultivate them and for the understanding of their biological process. He is also known for his contribution to the study of tumour development.
Recently, Dr. Petriz and his team’s interests focus on the basic mechanisms that regulate stem cells, examining the different genes involved in different aspects of their activation, and their resistance to multiple drugs. Their projects also use flow cytometry to analyse the genes that regulate cancer infiltration into the bone marrow. It is because of this that the Josep Carreras Leukaemia Institute was interested in this new team, in order to research flow cytometry further, a field that can offer new chances within the investigation of leukaemia and other malignant haemopaties.
Dr. Petriz’s team plays an essential role in encouraging the exchange between science and research and industry. The Josep Carreras Leukaemia Institute was established and is developed on the basis of translational research that strives to transfer the results of basic research to clinical implementation. Flow cytometry can be based on diagnosis, detecting interesting cell populations, counting them, marking them and/or isolating them depending on specific properties. Its uses are highly interesting in relation to designing new clinical trials with the pharmaceutical industry’s support in order to test new drugs that might improve the quality of life of the patients, maximise their response to the treatments and even cure the disease.
Because of this, Dr. Petriz will work very closely with all the other teams in the IJC, focused on the research of diseases such as leukaemia, lymphomas, multiple myeloma or myelodysplastic syndromes, among other haematologic neoplasms.
The common strategic objectives of the IJC are to understand the origins and development of leukaemia and other haematologic diseases, to identify new therapeutic goals for applying more precise and less aggressive treatments and to contribute these diseases becoming curable in 100% of the cases.
